This inventor holds 1 USPTO granted patent. Top assignee: Celdara Medical, LLC. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Ebo D De Muinck: Innovator in Dendritic Cell Modulation
Introduction
Ebo D De Muinck is a notable inventor based in Hanover, NH (US). He has made significant contributions to the field of medical science, particularly in the area of dendritic cell modulation. His work focuses on innovative methods to promote healing in ischemia-related injuries.
Latest Patents
Ebo D De Muinck holds a patent for "Dendritic cell modulation in post-ischemic wounds." This patent encompasses compositions and methods that are useful for the targeted depletion or modulation of dendritic cells. The inventive methods can be applied to enhance healing in conditions such as myocardial infarction, stroke, and critical limb ischemia. The patent details a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists.
Career Highlights
Ebo D De Muinck is associated with Celdara Medical, LLC, where he continues to advance his research and innovations. His work is pivotal in developing therapeutic strategies that address critical medical conditions.
Collaborations
Ebo collaborates with esteemed colleagues, including Jose R Conejo-Garcia, to further enhance the impact of his research in the medical field.
Conclusion
Ebo D De Muinck's contributions to dendritic cell modulation represent a significant advancement in medical science. His innovative approaches hold promise for improving treatment outcomes in ischemia-related injuries.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile